Srikala S. Sridhar
Publications by Year
Research Areas
Bladder and Urothelial Cancer Treatments, Urinary and Genital Oncology Studies, Prostate Cancer Treatment and Research, Cancer Immunotherapy and Biomarkers, Renal cell carcinoma treatment
Most-Cited Works
- → Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial(2016)2,185 cited
- → Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma(2020)1,443 cited
- → Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma(2017)842 cited
- → Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial(2020)489 cited
- → Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors(2023)435 cited
- → Rucaparib or Physician’s Choice in Metastatic Prostate Cancer(2023)392 cited
- → EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma(2020)315 cited
- → Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic(2017)303 cited
- → Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer(2014)296 cited
- → Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer(2003)281 cited